[1]潘莹,黄思超,王霞,等.NF-κB亚单位p50/p65激活促进肺腺癌H1650细胞吉非替尼耐药[J].南方医科大学学报,2018,(05):584.
点击复制

NF-κB亚单位p50/p65激活促进肺腺癌H1650细胞吉非替尼耐药()
分享到:

《南方医科大学学报》[ISSN:/CN:]

卷:
期数:
2018年05期
页码:
584
栏目:
出版日期:
2018-05-15

文章信息/Info

Title:
Activation of nuclear factor-κB subunit p50/p65 enhances gefitinib resistance of lung adenocarcinoma H1650 cell line
作者:
潘莹黄思超王霞龚五星梁翠微杜均祥彭东旭谢云郑礼平张楠全文
关键词:
肺腺癌活化的B细胞核因子κ-轻链增强子磷酸化p50和p65H1650细胞株吡咯烷二硫代氨基甲酸盐
Keywords:
lung adenocarcinoma nuclear factor kappa-light chain enhancer of activated B cells Phospho-p50 and Phosphop65 H1650 cell line pyrrolidine dithiocarbamate salt
摘要:
目的探究NF-κB经典通路激活与人肺腺癌H1650细胞吉非替尼耐药的内在联系。方法选择肺腺癌HCC827和H1650 亲代细胞株,吉非替尼连续处理60 d,检测细胞株生长情况和各细胞株595nm吸光度,确定各细胞株细胞存活率和H1650亲代 细胞被诱导成H1650耐药细胞株。Western blot检测各细胞株P-IκBα、NF-κB P-p50和P-p65表达量,Image J灰度仪计算出胞浆 和胞核P-p50和P-p65与内参蛋白灰度比值,比较吉非替尼和吉非替尼加吡咯烷二硫代氨基甲酸盐(PDTC)联合用药状态下,各 细胞株细胞存活率和P-IκB、P-p50和P-p65的表达。结果在无吉非替尼和吉非替尼加PDTC药物干预下,H1650耐药细胞PIκBα 表达增加,胞浆和胞核P-p50和P-p65表达,H1650耐药细胞株>H1650亲本细胞株>吉非替尼敏感HCC827细胞株(P<0.05, P<0.01);单独使用吉非替尼干预,H1650 耐药细胞株细胞抑制率较H1650 亲本细胞株和HCC827 细胞株降低(P<0.05,P< 0.01),H1650耐药细胞株P-p50和P-p65表达较其他两类细胞株升高(P<0.05);与无吉非替尼干预比较,H1650亲代和耐药细胞 P-p50和P-p65均有显著降低(P<0.05,P<0.01);吉非替尼联合PDTC干预,显示H1650亲代和耐药细胞存活率、胞浆和胞核Pp50 和P-p65表达均较吉非替尼组降低(P<0.01,P<0.01)。结论NF-κB经典传导通路激活是H1650亲代细胞残存和转化为吉 非替尼耐药细胞的主要因素之一,吉非替尼联合PDTC用药可抑制P-IκBα生成和P-p50、P-p65的激活,从而降低H1650残存细 胞生存率和耐药细胞的产生。
Abstract:
Objective To explore the intrinsic connection between activation of classical nuclear factor-κB (NF-κB) pathway and gefitinib resistance in human lung adenocarcinoma H1650 cells. Methods Human lung adenocarcinoma H1650 cells were exposed to gefitinib continuously for 60 days to obtain resistant H1650 cells. The expressions of P-IκBα, P-p50 and P-p65 in the cytoplasm or nuclei were detected using Western blotting in human lung adenocarcinoma HCC827 cells, parental H1650 cells and gefitinib-resistant H1650 cells. The effects of gefitinib alone or in combination with PDTC on the survival rate and expressions of NF-κB P-p50 and P-p65 were compared among the 3 cell lines. Results Gefitinib-resistant H1650 cells showed increased cytoplasmic and nuclear P-IκBα expressions. The expressions of P-p50 and P-p65 differed significantly among the 3 cell line, decreasing in the order of resistant H1650 cells, parental H1650 cells, and gefitinib sensitive HCC827 cell lines (P<0.05 or 0.01). Treatment with gefitinib alone resulted in a significantly lower cell inhibition rate in resistant H1650 cells than in the parental H1650 cells (P<0.05) and HCC827 cells (P<0.01). The resistant H1650 cells had a significantly higher expression of P-p50 and P-p65 than other two cell lines (P<0.05). In both the resistant and parental H1650 cells, gefitinib significantly lowered P-p50 and P-p65 expressions (P<0.05 or 0.01), and the combined treatment with gefitinib and PDTC significantly decreased the cell survival rate and further lowered the cytoplasmic and nuclear expressions of P-p50 and P-p65 (P<0.01 or 0.01). Conclusion The activation of classical NF- κB pathway is a key factor contributing to transformation of the parental H1650 cells into gefitinib-resistant cells. Gefitinib combined with PDTC can inhibit P-IκBα production and NF-κB P-p50 and P-p65 activation to suppress the survival of residual H1650 cells and the generation of gefitinib-resistant cells.

相似文献/References:

[1]宋海星,胡洪华.羟基喜树碱抑制肺癌A549细胞的体外增殖并下调Bcl-2基因的表达[J].南方医科大学学报,2012,(09):1341.
[2]赵晓,燕翔,孙胜杰,等.晚期肺腺癌患者外周血T淋巴细胞亚群检测的临床意义[J].南方医科大学学报,2012,(05):752.
[3]李慧灵,邓秋华,黄丽燕,等.磷脂酰肌醇蛋白聚糖-3在肺鳞癌和腺癌中的不同表达及其与预后的关系[J].南方医科大学学报,2013,(02):212.
[4]傅伟,彭辉,陈志强,等.罕见肺腺癌前列腺转移1例报告并文献复习[J].南方医科大学学报,2014,(02):289.
[5]徐小艳,刘红伟,姜黄,等.联合检测细胞蜡块中的napsin A和甲状腺转录因子-1有助于肺腺癌胸水的诊断[J].南方医科大学学报,2015,(11):1610.

更新日期/Last Update: 1900-01-01